$NBIO PTB recently completed its landmark Phase I
Post# of 103036
As noted in its most recent release, its Phase I clinical trial evaluating safety and tolerance for PTB as a treatment for Primary and Metastatic Brain Cancers has been completed, and Nascent pledges to continue to collect and evaluate the Clinical data from the Phase I trial while readying its submission to the U.S. FDA for Phase II consideration.
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.